Personalized Prostate Cancer Screening: Improving PSA Tests with Genomic Information

See allHide authors and affiliations

Science Translational Medicine  15 Dec 2010:
Vol. 2, Issue 62, pp. 62ps55
DOI: 10.1126/scitranslmed.3001861

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The use of a prostate-specific antigen (PSA) test to screen for prostate cancer is controversial because of its modest predictive value and the potential overdiagnosis and over-treatment of the disease. A research article in this issue of Science Translational Medicine describes single-nucleotide polymorphisms (SNPs) in or near six genes that are independently associated with serum PSA concentrations and that help to explain interindividual PSA variation. Three of these SNPs are also associated with prostate biopsy outcomes. These findings are an important step toward incorporating genetic markers into PSA screening, with the ultimate goal of devising personalized PSA tests for use in the clinic.


  • Citation: J. S. Witte, Personalized prostate cancer screening: Improving PSA tests with genomic information. Sci. Transl. Med. 2, 62ps55 (2010).

View Full Text

Stay Connected to Science Translational Medicine